Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Pulmonary Myoepithelial Tumors With Exuberant Reactive Pneumocytes: Proposed Reclassification of So-called Pneumocytic Adenomyoepithelioma.

Yuan L, Katabi N, Antonescu CR, Golden A, Travis WD, Rekhtman N.

Am J Surg Pathol. 2019 Sep 23. doi: 10.1097/PAS.0000000000001376. [Epub ahead of print]

PMID:
31567188
2.

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.

Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, Cotzia P, Kris MG, Rekhtman N, Young RJ, Hyman DM, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00021. Epub 2019 Jun 3. No abstract available.

3.

Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.

Chang JC, Alex D, Bott M, Tan KS, Seshan V, Golden A, Sauter JL, Buonocore DJ, Vanderbilt CM, Gupta S, Desmeules P, Bodd FM, Riely GJ, Rusch VW, Jones DR, Arcila ME, Travis WD, Ladanyi M, Rekhtman N.

Clin Cancer Res. 2019 Aug 30. doi: 10.1158/1078-0432.CCR-19-1700. [Epub ahead of print]

PMID:
31471310
4.

Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.

Zhou J, Sanchez-Vega F, Caso R, Tan KS, Brandt WS, Jones GD, Yan S, Adusumilli PS, Bott M, Huang J, Isbell JM, Sihag S, Molena D, Rusch VW, Chatila WK, Rekhtman N, Yang F, Ladanyi M, Solit DB, Berger MF, Schultz N, Jones DR.

Clin Cancer Res. 2019 Aug 27. doi: 10.1158/1078-0432.CCR-19-1651. [Epub ahead of print]

PMID:
31455678
5.

CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.

Buonocore DJ, Konno F, Jungbluth AA, Frosina D, Fayad M, Edelweiss M, Lin O, Rekhtman N.

Cancer Cytopathol. 2019 Oct;127(10):643-649. doi: 10.1002/cncy.22170. Epub 2019 Aug 9.

PMID:
31398281
6.

CytoJounal quiz case: Fine-needle aspiration of peripancreatic mass clinically mimicking a lymphoma.

Cimic A, Rekhtman N.

Cytojournal. 2019 May 24;16:11. doi: 10.4103/cytojournal.cytojournal_34_18. eCollection 2019. No abstract available.

7.

Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas.

Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N, Travis WD, Adusumilli PS.

J Thorac Oncol. 2019 Nov;14(11):1948-1961. doi: 10.1016/j.jtho.2019.07.008. Epub 2019 Jul 25.

PMID:
31352072
8.

Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.

Laddha SV, da Silva EM, Robzyk K, Untch BR, Ke H, Rekhtman N, Poirier JT, Travis WD, Tang LH, Chan CS.

Cancer Res. 2019 Sep 1;79(17):4339-4347. doi: 10.1158/0008-5472.CAN-19-0214. Epub 2019 Jul 12.

PMID:
31300474
9.

Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity.

Rekhtman N, Travis WD.

J Thorac Oncol. 2019 Jul;14(7):1125-1127. doi: 10.1016/j.jtho.2019.04.014. No abstract available.

PMID:
31235033
10.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA.

J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.

PMID:
31228622
11.

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.

Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00386. Epub 2019 May 16. No abstract available.

12.

Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.

Aly RG, Rekhtman N, Li X, Takahashi Y, Eguchi T, Tan KS, Rudin CM, Adusumilli PS, Travis WD.

J Thorac Oncol. 2019 Sep;14(9):1583-1593. doi: 10.1016/j.jtho.2019.05.009. Epub 2019 May 20.

PMID:
31121325
13.

Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee.

Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Review.

PMID:
31050216
14.

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.

Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, Riely GJ.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003665. doi: 10.1101/mcs.a003665. Print 2019 Apr.

15.

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.

Rekhtman N, Desmeules P, Litvak AM, Pietanza MC, Santos-Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, Sabari JK, Rudin CM, Ladanyi M, Klimstra DS, Travis WD, Lai WC.

Mod Pathol. 2019 Jul;32(8):1106-1122. doi: 10.1038/s41379-019-0248-2. Epub 2019 Mar 28.

16.

Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics.

Silk MT, Mikkilineni N, Silk TC, Zabor EC, Ostrovnaya I, Hakimi AA, Hsieh JJ, Ziv E, Rekhtman N, Solomon SB, Durack JC.

Anal Cell Pathol (Amst). 2018 Dec 10;2018:2898962. doi: 10.1155/2018/2898962. eCollection 2018.

17.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
18.

Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J, Chang JC, Rekhtman N, Jones DR, Travis WD, Adusumilli PS.

J Thorac Oncol. 2019 Jan;14(1):87-98. doi: 10.1016/j.jtho.2018.09.005. Epub 2018 Sep 19.

PMID:
30244070
19.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

20.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.

21.

Type A thymoma presenting with bone metastasis.

Montecalvo J, Chang J, Rekhtman N, Antonescu CR, Bains MS, Fabbri N, Plodkowski AJ, Riely GJ, Travis WD, Sauter JL.

Histopathology. 2018 Oct;73(4):701-703. doi: 10.1111/his.13662. Epub 2018 Jul 8. No abstract available.

PMID:
29855070
22.

Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases.

Chang JC, Montecalvo J, Borsu L, Lu S, Larsen BT, Wallace WD, Sae-Ow W, Mackinnon AC, Kim HR, Bowman A, Sauter JL, Arcila ME, Ladanyi M, Travis WD, Rekhtman N.

Am J Surg Pathol. 2018 Aug;42(8):1010-1026. doi: 10.1097/PAS.0000000000001086.

PMID:
29846186
23.

Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.

Funkhouser WK Jr, Hayes DN, Moore DT, Funkhouser WK 3rd, Fine JP, Jo H, Nikolaishvilli-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, Graziano P, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Hariri L, Driver B, Cagle PT.

Arch Pathol Lab Med. 2018 Dec;142(12):1537-1548. doi: 10.5858/arpa.2017-0481-OA. Epub 2018 Apr 30.

PMID:
29708428
24.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

25.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD.

Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.

26.

Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Turner SR, Buonocore D, Desmeules P, Rekhtman N, Dogan S, Lin O, Arcila ME, Jones DR, Huang J.

Lung Cancer. 2018 May;119:85-90. doi: 10.1016/j.lungcan.2018.03.003. Epub 2018 Mar 7.

27.

Commentary on Testing of Non-Adenocarcinomas.

Rekhtman N.

Arch Pathol Lab Med. 2018 Jul;142(7):798. doi: 10.5858/arpa.2018-0065-ED. Epub 2018 Apr 12. No abstract available.

PMID:
29648885
28.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

29.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645.

30.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. No abstract available.

31.

Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies.

Rekhtman N, Buonocore DJ, Rudomina D, Friedlander M, Dsouza C, Aggarwal G, Arcila M, Edelweiss M, Lin O.

Arch Pathol Lab Med. 2018 Apr;142(4):529-535. doi: 10.5858/arpa.2017-0030-OA. Epub 2017 Nov 2.

PMID:
29095036
32.

Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.

Rekhtman N, Pietanza CM, Sabari J, Montecalvo J, Wang H, Habeeb O, Kadota K, Adusumilli P, Rudin CM, Ladanyi M, Travis WD, Joubert P.

Mod Pathol. 2018 Jan;31(1):111-121. doi: 10.1038/modpathol.2017.110. Epub 2017 Sep 8.

33.

Erratum to: Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, Adusumilli PS, Rekhtman N, Solomon SB, Ziv E.

Cardiovasc Intervent Radiol. 2017 Oct;40(10):1658. doi: 10.1007/s00270-017-1767-1. No abstract available.

PMID:
28799111
34.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ, Hellmann MD.

PLoS One. 2017 Aug 3;12(8):e0182665. doi: 10.1371/journal.pone.0182665. eCollection 2017.

35.

Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, Adusumilli P, Rekhtman N, Solomon SB, Ziv E.

Cardiovasc Intervent Radiol. 2018 Feb;41(2):253-259. doi: 10.1007/s00270-017-1760-8. Epub 2017 Aug 2. Erratum in: Cardiovasc Intervent Radiol. 2017 Aug 10;:.

36.

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.

Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):408-419. doi: 10.5858/arpa.2017-0106-SA. Epub 2017 Jul 7.

PMID:
28686497
37.

Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Jain D, Allen TC, Aisner DL, Beasley MB, Cagle PT, Capelozzi VL, Hariri LP, Lantuejoul S, Miller R, Mino-Kenudson M, Monaco SE, Moreira A, Raparia K, Rekhtman N, Roden AC, Roy-Chowdhuri S, da Cunha Santos G, Thunnissen E, Troncone G, Vivero M.

Arch Pathol Lab Med. 2018 Feb;142(2):253-262. doi: 10.5858/arpa.2017-0114-SA. Epub 2017 Jun 22. Review.

PMID:
28639854
38.

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.

Schilsky JB, Ni A, Ahn L, Datta S, Travis WD, Kris MG, Chaft JE, Rekhtman N, Hellmann MD.

Lung Cancer. 2017 Jun;108:205-211. doi: 10.1016/j.lungcan.2017.03.015. Epub 2017 Mar 28.

39.

A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.

Desmeules P, Joubert P, Zhang L, Al-Ahmadie HA, Fletcher CD, Vakiani E, Delair DF, Rekhtman N, Ladanyi M, Travis WD, Antonescu CR.

Am J Surg Pathol. 2017 Jul;41(7):980-988. doi: 10.1097/PAS.0000000000000864.

40.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

41.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

42.

Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.

Sigel CS, Guo H, Sigel KM, Zhang M, Rekhtman N, Lin O, Klimstra DS, Jungbluth AA, Tang LK.

Cancer Cytopathol. 2017 Mar;125(3):188-196. doi: 10.1002/cncy.21817. Epub 2017 Jan 17.

43.

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Jakubowski CD, Plodkowski AJ, Chang JC, Rekhtman N, Iqbal A, Paik PK, Yu HA.

Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26. No abstract available.

44.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

45.

Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society.

Roden AC, Aisner DL, Allen TC, Aubry MC, Barrios RJ, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Ge Y, Hariri LP, Lantuejoul S, Miller RA, Mino-Kenudson M, Moreira AL, Raparia K, Rekhtman N, Sholl L, Smith ML, Tsao MS, Vivero M, Yatabe Y, Yi ES.

Arch Pathol Lab Med. 2017 Mar;141(3):437-444. doi: 10.5858/arpa.2016-0459-SA. Epub 2016 Nov 7.

PMID:
27819763
46.

Cytology Specimens: A Goldmine for Molecular Testing.

Rekhtman N, Roy-Chowdhuri S.

Arch Pathol Lab Med. 2016 Nov;140(11):1189-1190. No abstract available.

PMID:
27788046
47.

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Lu S, Tan KS, Kadota K, Eguchi T, Bains S, Rekhtman N, Adusumilli PS, Travis WD.

J Thorac Oncol. 2017 Feb;12(2):223-234. doi: 10.1016/j.jtho.2016.09.129. Epub 2016 Sep 28.

48.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

49.

Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience.

Tian SK, Killian JK, Rekhtman N, Benayed R, Middha S, Ladanyi M, Lin O, Arcila ME.

Arch Pathol Lab Med. 2016 Sep 2. [Epub ahead of print]

PMID:
27588332
50.

Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

Zakowski MF, Rekhtman N, Auger M, Booth CN, Crothers B, Ghofrani M, Khalbuss W, Laucirica R, Moriarty AT, Tabatabai ZL, Barkan GA.

Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23.

Supplemental Content

Loading ...
Support Center